PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media290001ArticlesСтатьиResearch ArticleNew possibilities of the treatment of breast cancer: microtubule inhibitorsНовые возможности лечения рака молочной железы: ингибиторы микротрубочекSemiglazovV. FСемиглазовВ. ФDashyanG. AДашянГ. А

MD, Leading Researcher at the Department of Breast Tumors

д.м.н., ведущий научн. сотр. отделения опухолей молочной железы

dgarik@mail.ruKrivorotkoP. VКриворотькоП. ВPaltuevR. MПалтуевР. МDonskikhR. VДонскихР. ВSemiglazovaT. YuСемиглазоваТ. ЮZernovK. YЗерновК. ЮGigolaevaL. PГиголаеваЛ. ПApollonovaV. SАполлоноваВ. СFSBI «SRI of Oncology n.a. N.N. Petrov» of RMHФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России100920172417NO17 (2017)№17 (2017)454926022023Copyright ©; 2017, Bionika MediaCopyright ©; 2017, ООО «Бионика Медиа»2017Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/290001

Breast cancer (BC) is a biologically heterogeneous disease, and approximately 15-20% of the cases is accounted for by triple negative variant (ER/PR/HER2-negative), which is characterized by a relatively high frequency of progression and mortality. The place of eribulin mesylate in the treatment of this form of cancer is discussed. The target of eribulin action is tubulin. Currently, possibility of combination of eribulin with capecitabine is studied. It was concluded that the appearance of new drug with the original mechanism of action, eribulin mesylate, in the clinical oncology expands the possibilities of effective therapeutic effects not only in metastatic ER-negative and triple-negative forms of breast cancer resistant to standard therapeutic interventions, but also in the earlier stages of the disease.

Рак молочной железы (РМЖ) представляет собой биологически гетерогенное заболевание, и приблизительно 15-20% его случаев приходится на трижды негативный вариант (ЭР/ПР/HER2-отрицательный), характеризующийся сравнительно высокой частотой прогрессирования и смертности. Рассматривается место в лечении этой формы рака эрибулина мезилата, мишенью действия которого является тубулин. В настоящее время изучается возможность комбинации эрибулина с капецитабином. Сделан вывод, согласно которому появление в клинической онкологии нового лекарственного препарата с оригинальным механизмом действия - эрибулина мезалата, расширяет возможности эффективного терапевтического воздействия не только при метастатических ER-негативных и трижды негативных формах РМЖ, резистентных к стандартным лечебным мероприятиям, но и при более ранних стадиях заболевания.

breast cancertriple negative subtypetubulineribulin mesylatecapecitabineрак молочной железытрижды негативный подтиптубулинэрибулина мезилаткапецитабинСемиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Клинические рекомендации по диагностике и лечению рака молочной железы. М., 2013. 234 с.Артамонова Е.В., Горбунова В.А., Жуков Н.В., Манзюк Л.В., Манихас А.Г., Палтуев Р.М, Семиглазов В.Ф, Семиглазова Т.Ю, Стенина М.Б., Тюляндин С.А., Чубенко В.А. Трудности в лечении больных раком молочной железы в России: резолюция по итогам Экспертного Совета. Современная онкология. 2014;16(2).Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., Littlefield B.A., Wilson L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 2005;4:1086-95.Okouneva T., Azarenko O.,Wilson L.,Littlefield B.A., Jordan M.A. Inhibition of Centromere Dynamics by Eribulin (E7389) during Mitotic Metaphase. Mol. Cancer Ther. 2008;7(7): 2003-11.Yoshida T., Ozawa Y., Kimura T., Sato Y., Kuznetsov G., Xu S., Uesugi M., Agoulnik S., Taylor N., Funahashi Y., Matsui J. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br. J. Cancer. 2014;110:1497-505.Twelves C., Evans J., Semiglazov V.F. A phase 1b/2 milticentr, open-label, dose escalation (in solid tumors) and dose confirmaxion (in advanced and/or metastatic cancer). Study of Eribulin Mesalate in combination with Capecitabine. Ann. Oncol. 2015;26.Towle M.J., Salvato K.A., Budrow J., Wels B.F., Kuznetsov G., Aalfs K.K., Welsh S., Zheng W., Seletsky B.M., Palme M.H., Habgood G.J., Singer L.A., Dipietro L.V., Wang Y., Chen J.J., Quincy D.A., Davis A., Yoshimatsu K., Kishi Y., Yu M.J., Littlefield B.A. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61(3):1013-21.Kuznetsov G., TenDyke K., Yu M.J., et al. Andproliferative effects of halichondrin В analog eribulin mesylate (E7389) against paclitaxelresistant human cancer cells in vitro. Proc. Am. Assoc. Cancer Res. 2007;489(275):abstr. 58.Goel S., Mita A.C., Mita M., Rowinsky E.K., Chu Q.S., Wong N., Desjardins C., Fang F., Jansen M., Shuster D.E., Mani S., Takimoto C.H. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin. Cancer Res. 2009;15(12):4207-12.Morgan R.J., Synold T.W., Longmate J.A., Quinn D.I., Gandara D., Lenz H.J., Ruel C., Xi B., Lewis M.D., Colevas A.D., Doroshow J., Newman E.M. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother. Pharmacol. 2015;76(5):897-907.Tan A.R., Rubin E.H., Walton D.C., Shuster D.E., Wong Y.N., Fang F., Ashworth S., Rosen L.S. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin. Cancer Res. 2009;15(12): 4213-19.Mukohara T., Nagai S., Mukai H., Namiki M., Minami H. Eribulin mesylate in patients with refractory cancers: a phase I study. Invest. New Drugs. 2012;30(5):1926-33.Vahdat L.T., Pruitt B., Fabian C.J., Rivera R.R., Smith D.A., Tan-Chiu E., Wright J., Tan A.R., Dacosta N.A., Chuang E., Smith J., O'Shaughnes-sy J., Shuster D.E., Meneses N.L., Chandrawansa K., Fang F., Cole R.E., Ashworth S., Blum J.L. Phase II study of eribulin mesylate, a halichondrin В analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Clin. Oncol. 2009;27(18): 2954-61.Cortes J., Vahdat L., Blum J.L., Twelves C., Campone M., Roche H., Bachelot T., Awada A., Paridaens R., Goncalves A., Shuster D.E., Wanders J., Fang F., Gurnani R., Richmond E., Cole P.E., Ashworth S., Allison M.A. Phase II study of the halichondrin В analog eribulin mesylate in patients with locally advanced or meta static breast cancer previously treated -with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 2010;28(25):3922-28.Aogi K., Iwata H., Masuda N., Mukai H., Yoshida M., Rai Y., Taguchi K., Sasaki Y., Takashima S. A Phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann. Oncol. 2012;23(6):1441-48.Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., Chollet P, Manikas A., Dieras V., Delozier T, Vladimirov V, Cardoso F., Koh H., Bougnoux R., Dutcus C.E., Seegobin S., Mir D., Meneses N., Wanders J., Twelves C. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study. Lancet. 2011;377(9769):914-23.Kaufman R.A., Awada A., Twelves C., Yelle L., Perez E.A., Wanders J., Olivo M.S.,He Y., Dutcus C.E. A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res. 2012;72(24 Suppl):abstr. S6.Goodin S., Barbour S., Song J., Berrak E., Cox D. Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer. Am. J. Health Syst. Pharm. 2015;72(24): 2150-56.Funahashi Y., Okamoto K., Adachi Y, Semba T, Uesugi M., Ozawa Y., Tohyama O., Uehara T., Kimura T., Watanabe H., Asano M., Kawano S., Tizon X., McCracken PJ., Matsui J., Aoshima K., Nomoto K, Oda Y. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci. 2014; 105(10):1334-42.Doherty M.K., Morris R.G. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int. J. Womens Health. 2015;7:47-58.O'Shaughnessy J. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Williston Park). 2002;16(10 Suppl 12):17-22.Gelmon K., Chan A., Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist. 2006;11(Suppl 1):42-51.Yardley D.A., Chandra P, Hart L., Wright G.S., Ward P., Mani A., Shastry M., Finney L., Guo S., DeBusk L.M., Hainsworth J.D., Burris III H.A. A phase II randomized study with eribulin/ ceclophosphamide (ErC) and docetaxel/ cyclophosphamide (TC) as neoadjuvant therapy in HER2-negative breast cancer - final analysis of primary endpoint and correlative analysis results. 2015 San Antonio Breast Cancer Symposium.